Showing results (51-60 of 124) with videos related to
Sort By:
Pageof 13
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 28, 2026
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosisMarcus Koch, Jop Mostert, Eva M Strijbis, et al.Neurology|February 17, 2025
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple SclerosisEva M M Strijbis, Jop Mostert, Jacynthe Comtois, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2023
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosisEva M Strijbis, Eline Coerver, Jop Mostert, et al.Radiology|September 11, 2014
Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosisVasily L Yarnykh, James D Bowen, Alexey Samsonov, et al.Multiple Sclerosis and Related Disorders|March 20, 2015
Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center dataSushmita Datta, Terrell D Staewen, Stacy S Cofield, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2004
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisA John Petkau, Richard A White, George C Ebers, et al.Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.Multiple Sclerosis and Related Disorders|July 13, 2021
Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 - Fatigue (MS) 8aPaul Kamudoni, Jeffrey Johns, Karon F Cook, et al.Therapeutic Advances in Neurological Disorders|April 2, 2021
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 studyAnnette Wundes, Sibyl Wray, Ralf Gold, et al.Pageof 13